Solid Biosciences Llc Stock Revenue
| SLDB Stock | USD 4.93 0.43 8.02% |
Solid Biosciences LLC fundamentals help investors to digest information that contributes to Solid Biosciences' financial success or failures. It also enables traders to predict the movement of Solid Stock. The fundamental analysis module provides a way to measure Solid Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Solid Biosciences stock.
| Last Reported | Projected for Next Year |
Solid | Revenue |
Solid Biosciences LLC Company Revenue Analysis
Solid Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Solid
Projected quarterly revenue analysis of Solid Biosciences LLC provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Solid Biosciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Solid Biosciences' stock price.
Solid Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Solid Biosciences is extremely important. It helps to project a fair market value of Solid Stock properly, considering its historical fundamentals such as Revenue. Since Solid Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Solid Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Solid Biosciences' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Solid Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Solid Biosciences LLC reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Solid Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Solid Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Solid Biosciences could also be used in its relative valuation, which is a method of valuing Solid Biosciences by comparing valuation metrics of similar companies.Solid Biosciences is currently under evaluation in revenue category among its peers.
Solid Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Solid Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Solid Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Solid Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Solid Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Solid Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Solid Biosciences' value.| Shares | Millennium Management Llc | 2024-12-31 | 719.8 K | Redmile Group, Llc | 2024-12-31 | 615.2 K | Geode Capital Management, Llc | 2024-12-31 | 509.8 K | Monashee Investment Management Llc | 2024-12-31 | 480 K | State Street Corp | 2024-12-31 | 432.2 K | Alyeska Investment Group, L.p. | 2024-12-31 | 346.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 264.1 K | Laurion Capital Management Lp | 2024-12-31 | 255.1 K | Nuveen Asset Management, Llc | 2024-12-31 | 197.9 K | Perceptive Advisors Llc | 2024-12-31 | 6.9 M | Ra Capital Management, Llc | 2024-12-31 | 4.3 M |
Solid Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 269.7 M | ||||
| Shares Outstanding | 77.49 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 62.23 % | ||||
| Number Of Shares Shorted | 2.95 M | ||||
| Price To Book | 2.87 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (96.43 M) | ||||
| EBITDA | (129.73 M) | ||||
| Net Income | (124.7 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 24.18 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 3.39 X | ||||
| Cash Flow From Operations | (100.01 M) | ||||
| Short Ratio | 1.50 X | ||||
| Earnings Per Share | (3.06) X | ||||
| Target Price | 16.7 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.98 | ||||
| Market Capitalization | 415.36 M | ||||
| Total Asset | 188.66 M | ||||
| Retained Earnings | (783.45 M) | ||||
| Working Capital | 127.05 M | ||||
| Net Asset | 188.66 M |
About Solid Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Solid Biosciences LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Solid Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Solid Biosciences LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out Solid Biosciences Piotroski F Score and Solid Biosciences Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.